Trials / Completed
CompletedNCT01450579
A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers
Phase II Study of ASP7373 Evaluation of Immunogenicity and Safety of ASP7373 in Healthy Adults
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- UMN Pharma Inc. · Industry
- Sex
- All
- Age
- 20 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
This trial is to investigate the clinically recommended dosage for ASP7373 based on the comparison of the immunogenicity and safety among the three doses of ASP7373 in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ASP7373 | Intermuscular administration |
| BIOLOGICAL | Placebo | Intramuscular administration |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2011-10-12
- Last updated
- 2017-09-29
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01450579. Inclusion in this directory is not an endorsement.